NO963984D0 - New, 1,4-disubstituted piperidine derivatives useful as drugs acting on glutamate receptors - Google Patents

New, 1,4-disubstituted piperidine derivatives useful as drugs acting on glutamate receptors

Info

Publication number
NO963984D0
NO963984D0 NO963984A NO963984A NO963984D0 NO 963984 D0 NO963984 D0 NO 963984D0 NO 963984 A NO963984 A NO 963984A NO 963984 A NO963984 A NO 963984A NO 963984 D0 NO963984 D0 NO 963984D0
Authority
NO
Norway
Prior art keywords
new
glutamate receptors
derivatives useful
piperidine derivatives
drugs acting
Prior art date
Application number
NO963984A
Other languages
Norwegian (no)
Other versions
NO963984L (en
Inventor
Dieter Seidelmann
Andreas Huth
Martin Kruger
Eckhard Ottow
Graham Jones Jones
Roland Neuhaus
Lechoslaw Turski
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO963984D0 publication Critical patent/NO963984D0/en
Publication of NO963984L publication Critical patent/NO963984L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO963984A 1994-03-24 1996-09-23 New, 1,4-disubstituted piperidine derivatives useful as drugs acting on glutamate receptors NO963984L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4410822A DE4410822A1 (en) 1994-03-24 1994-03-24 New piperidine derivatives
PCT/DE1995/000442 WO1995025721A1 (en) 1994-03-24 1995-03-23 New 1,4-disubstituted piperidine derivatives useful as medicaments acting on the glutamate receptor

Publications (2)

Publication Number Publication Date
NO963984D0 true NO963984D0 (en) 1996-09-23
NO963984L NO963984L (en) 1996-09-23

Family

ID=6514110

Family Applications (1)

Application Number Title Priority Date Filing Date
NO963984A NO963984L (en) 1994-03-24 1996-09-23 New, 1,4-disubstituted piperidine derivatives useful as drugs acting on glutamate receptors

Country Status (16)

Country Link
EP (1) EP0751936A1 (en)
JP (1) JPH09510460A (en)
KR (1) KR970701695A (en)
CN (1) CN1145618A (en)
AU (1) AU2212595A (en)
CA (1) CA2186010A1 (en)
CZ (1) CZ277096A3 (en)
DE (1) DE4410822A1 (en)
FI (1) FI963786A (en)
HU (1) HUT75653A (en)
IL (1) IL113103A0 (en)
NO (1) NO963984L (en)
PL (1) PL316382A1 (en)
SK (1) SK120196A3 (en)
WO (1) WO1995025721A1 (en)
ZA (1) ZA952431B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9610736B (en) 1995-12-22 1997-06-27 Warner Lambert Co 2-Substituted piperidine analogs and their use as subtypeselective nmda receptor antagonists
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
PT885004E (en) * 1996-03-08 2002-08-30 Hoffmann La Roche USING 4-PHENYL-3,6-DIHYDRO-2H-PYRIDYL DERIVATIVES AS BLOCKERS OF NMDA RECEPTOR SUBTYPES
US6017903A (en) 1996-09-27 2000-01-25 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors
US5824662A (en) 1996-09-27 1998-10-20 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using naaladase inhibitors
EP1005348A1 (en) 1996-09-27 2000-06-07 Guilford Pharmaceuticals Inc. Naaladase compositions and methods for treating glutamate abnormality and effecting neuronal activity in animals
US6242450B1 (en) * 1998-07-27 2001-06-05 Eli Lilly And Company 5-HT1F antagonists
ATE266400T1 (en) * 1998-07-31 2004-05-15 Lilly Co Eli HETEROCYCLYL SULPHONAMIDE DERIVATIVES
EP1190710A4 (en) * 1999-05-13 2003-04-02 Shionogi & Co Preventive or therapeutic drugs for diabetes
TWI254043B (en) * 1999-06-08 2006-05-01 Hoffmann La Roche Ethanesulfonyl-piperidine derivatives having good affinity to N-methyl-D-aspartate (NMDA) receptor
DK1136475T3 (en) 2000-03-22 2004-12-27 Hoffmann La Roche Piperidine and piperazine derivatives for use in the treatment of Alzheimer's
US6407235B1 (en) 2000-08-21 2002-06-18 Hoffmann-La Roche Inc. Prodrug acid esters of [2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethansulfonyl]phenol
US6770659B2 (en) 2002-08-26 2004-08-03 Sk Corporation Benzoyl piperidine compounds
GB0224084D0 (en) 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
EP4092013A1 (en) 2017-06-20 2022-11-23 Imbria Pharmaceuticals, Inc. Compositions and methods for increasing efficiency of cardiac metabolism
CN110437136A (en) * 2019-07-30 2019-11-12 东南大学 1- virtue oxygen ethyl piperidine -4- base methanone derivatives and its preparation method and application
US11780811B2 (en) 2020-06-30 2023-10-10 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11530184B2 (en) 2020-06-30 2022-12-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3576810A (en) * 1968-06-20 1971-04-27 Robins Co Inc A H 1-substituted-3-(-4)-aroylpiperidines
DE2827566A1 (en) * 1978-06-23 1980-01-10 Boehringer Mannheim Gmbh 1,2-DIHYDRO-CHINOLIN-2-ON DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
WO1982003861A1 (en) * 1981-05-08 1982-11-11 Tominaga Michiaki Aniline derivatives,process for their preparation,and cardiotonics
PH19166A (en) * 1982-09-04 1986-01-16 Pfizer Dihydropyridined,pharmaceutical compositions and method of use
FR2534580A1 (en) * 1982-10-13 1984-04-20 Synthelabo PHENYL-1 PIPERIDINO-2 PROPANOL DERIVATIVES, THEIR PREPARATION, AND MEDICINES THAT CONTAIN THEM
DK623586A (en) * 1985-12-27 1987-06-28 Eisai Co Ltd PIPERIDE INGREDIENTS OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE COMPOUNDS
US4868181A (en) * 1986-08-04 1989-09-19 E. I. Du Pont De Nemours And Company 1,4-dihydropyridine derivatives with calcium agonist and alpha1 -antagonist activity
KR910006138B1 (en) * 1986-09-30 1991-08-16 에자이 가부시끼가이샤 Cyclic amine derivatives
EP0294183B1 (en) * 1987-06-02 1994-03-30 Ajinomoto Co., Inc. Use of ethylamine derivatives as antihypertensive agents
EP0424525B1 (en) * 1987-12-11 1994-12-21 Mitsui Petrochemical Industries, Ltd. Novel amines and their use
SU1731048A3 (en) * 1988-05-27 1992-04-30 Эйсай Ко., Лтд (Фирма) Process for preparing piperidine derivatives of pharmacolocically acceptable salts thereof
FR2632641B1 (en) * 1988-06-13 1990-10-12 Irceba ((ARYL-4-PIPERAZINYL-1) -2 ETHOXY) -3 P-CYMENE, ORTHO DERIVATIVES, META, PARA MONOSUBSTITUTED OR DISUBSTITUTED ON THE PHENYL CORE OF THIS PRODUCT, THE PROCESS FOR THE PREPARATION OF SUCH DERIVATIVES, AND THE MEDICINAL PRODUCTS AS ACTIVE PRINCIPLE
US5153198A (en) * 1989-03-15 1992-10-06 Santen Pharmaceutical Co., Ltd. Agent for treatment of disorders of the cerebro-neural transmission system
US5116846A (en) * 1990-03-28 1992-05-26 Du Pont Merck Pharmaceutical Company N-aralkyl piperidine derivatives as psychotropic drugs
FR2681319B1 (en) * 1991-09-12 1995-02-17 Synthelabo 1- (PHENOXYALKYL) PIPERIDINE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION.
ES2060547B1 (en) * 1992-06-04 1995-06-16 Ferrer Int IMPROVEMENTS IN THE PURPOSE OF THE INVENTION PATENT N / 9201158 THAT REFERS TO "PROCEDURE FOR OBTAINING NEW DERIVATIVES OF 4-BENCILPIPERIDINE".
FR2705343B1 (en) * 1993-05-17 1995-07-21 Fournier Ind & Sante Beta, beta-dimethyl-4-piperidineethanamine derivatives, process for their preparation and their use in therapy.

Also Published As

Publication number Publication date
WO1995025721A1 (en) 1995-09-28
DE4410822A1 (en) 1995-09-28
EP0751936A1 (en) 1997-01-08
AU2212595A (en) 1995-10-09
KR970701695A (en) 1997-04-12
HU9602607D0 (en) 1996-11-28
SK120196A3 (en) 1997-10-08
CA2186010A1 (en) 1995-09-28
FI963786A0 (en) 1996-09-23
CN1145618A (en) 1997-03-19
CZ277096A3 (en) 1997-01-15
IL113103A0 (en) 1995-06-29
NO963984L (en) 1996-09-23
HUT75653A (en) 1997-05-28
ZA952431B (en) 1995-12-19
JPH09510460A (en) 1997-10-21
MX9604201A (en) 1997-12-31
PL316382A1 (en) 1997-01-06
FI963786A (en) 1996-09-23

Similar Documents

Publication Publication Date Title
NO963984D0 (en) New, 1,4-disubstituted piperidine derivatives useful as drugs acting on glutamate receptors
DE69718026D1 (en) FLUORED 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES
DK0855999T3 (en) 1- (1,2-Disubstituted piperidinyl) -4-substituted piperidine derivatives as tachykinin receptor antagonists
DK0862566T3 (en) 1- (1,2-Disubstituted piperidinyl) -4-substituted piperazine derivatives
DK0804419T3 (en) Quinoline derivatives as tachykinin NK 3 receptor antagonists
NO20000356L (en) Substituted 1,2,3,4-tetrahydronaphthalene derivatives
DE69531331D1 (en) Phenylpiperidine derivatives as neurokinin antagonists
NO974686L (en) Novel substituted piperazine derivatives with tachykinin receptor antagonistic activity
NO980814D0 (en) New 2,3-dioxo-1,2,3,4-tetrahydroquinoxalinyl derivatives
NO954453D0 (en) New pyridine, pyrimidine and benzene derivatives as adrenoceptor antagonists
DK0885215T3 (en) New benzo-1,3-dioxolyl- and benzofuranyl-substituted pyrrolidine derivatives as endthelin antagonists
DE69830297D1 (en) Arylpiperazines have the effect on the serotonin 1a receptor
DE68906801D1 (en) 1,4-DISUBSTITUTED PIPERIDINE COMPOUNDS.
NO930306L (en) NEW 1,4-DIHYDROPYRIDINE DERIVATIVES
EE9800300A (en) Substituted 1,2,3,4-tetrahydronaphthalene derivatives
NO985970D0 (en) Indoline derivatives useful as 5_HT-2C receptor antagonists
AU3875095A (en) Piperazine, piperidine & tetrahydropyridine derivatives useful as 5-ht1 receptor agonists
NO993012D0 (en) New carboxy-substituted cyclic carboxamide derivatives
DK0815105T3 (en) Heterocyclic substituted piperazine derivatives as tachykinin receptor antagonists
FI943872A0 (en) 2,6-methono-2H-quinolithine derivative as a 5-HT 3 receptor antagonist
NO892772D0 (en) NEW 1,4-DIAZEPINE DERIVATIVES WITH ANTI-ULCUS ACTIVITY.
NO177566C (en) New 1,3-dioxane derivatives